Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Dopamine in amygdala gates limbic processing of aversive stimuli in humans

Abstract

Dopamine is released under stress and modulates processing of aversive stimuli. We found that dopamine storage capacity in human amygdala, measured with 6-[18F]fluoro-L-DOPA positron emission tomography, was positively correlated with functional magnetic resonance imaging blood oxygen level–dependent signal changes in amygdala and dorsal anterior cingulate cortex that were evoked by aversive stimuli. Furthermore, functional connectivity between these two regions was inversely related to trait anxiety. Our results suggest that individual dopamine storage capacity in amygdala subserves modulation of emotional processing in amygdala and dorsal cingulate, thereby contributing to individual differences in anxious temperament.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Correlation between FDOPA steady-state storage capacity (Vd) in the left amygdala and fMRI BOLD response elicited by negative versus neutral stimuli in the left amygdala in 13 healthy subjects.

References

  1. 1

    Schultz, W., Dayan, P. & Montague, P.R. Science 275, 1593–1599 (1997).

    CAS  Article  PubMed  Google Scholar 

  2. 2

    Pani, L., Porcella, A. & Gessa, G.L. Mol. Psychiatry 5, 14–21 (2000).

    CAS  Article  PubMed  Google Scholar 

  3. 3

    Panksepp, J. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 774–784 (2006).

    Article  PubMed  Google Scholar 

  4. 4

    Oswald, L.M. et al. Neuroimage 36, 153–166 (2007).

    Article  PubMed  Google Scholar 

  5. 5

    Rosenkranz, J.A. & Grace, A.A. Nature 417, 282–287 (2002).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    Hariri, A.R. et al. Neuropsychopharmacology 27, 1036–1040 (2002).

    CAS  Article  PubMed  Google Scholar 

  7. 7

    Tessitore, A. et al. J. Neurosci. 22, 9099–9103 (2002).

    CAS  Article  PubMed  Google Scholar 

  8. 8

    Manuck, S.B., Brown, S.M., Forbes, E.E. & Hariri, A.R. Am. J. Psychiatry 164, 1613–1614 (2007).

    Article  PubMed  Google Scholar 

  9. 9

    Kumakura, Y. et al. J. Neurosci. 27, 8080–8087 (2007).

    CAS  Article  PubMed  Google Scholar 

  10. 10

    Bush, G., Luu, P. & Posner, M.I. Trends Cogn. Sci. 4, 215–222 (2000).

    CAS  Article  PubMed  Google Scholar 

  11. 11

    Pezawas, L. et al. Nat. Neurosci. 8, 828–834 (2005).

    CAS  Article  PubMed  Google Scholar 

  12. 12

    Heinz, A. et al. Nat. Neurosci. 8, 20–21 (2005).

    CAS  Article  PubMed  Google Scholar 

  13. 13

    Friston, K.J. et al. Neuroimage 6, 218–229 (1997).

    CAS  Article  PubMed  Google Scholar 

  14. 14

    Kumakura, Y. et al. Neurobiol. Aging published online, doi:10.1016/j.neurobiolaging.2008.05.005 (9 June 2008).

  15. 15

    Deeley, Q. et al. Neuroimage 40, 389–397 (2008).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

FDOPA plasma metabolite analysis was performed by S. Hoehnemann (University of Mainz). This study was supported by the Deutsche Forschungsgemeinschaft (HE 2597/4-3, HE 2597/7-3 and SM 80/2-2). A.R.H. is supported by the National Alliance for Research on Schizophrenia and Depression and US National Institutes of Health grant MH072837.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Andreas Heinz.

Ethics declarations

Competing interests

Dr. Gründer has served as a consultant for Astra Zeneca, Bristol-Myers Squibb, Johnson & Johnson, Otsuka and Pfizer. He has served on the speakers' bureau of Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen Cilag, Otsuka, Pfizer, Servier and Wyeth. He has received grant support from Aventis, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson and Pfizer.

Supplementary information

Supplementary Text and Figures

Supplementary Figure 1, Supplementary Methods, Supplementary Discussion and Supplementary Results (PDF 884 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kienast, T., Hariri, A., Schlagenhauf, F. et al. Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci 11, 1381–1382 (2008). https://doi.org/10.1038/nn.2222

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing